Baclofen

Introduction Overview

Generic Name

baclofen

Brand Name

Lioresal, Lioresal Intrathecal, Gablofen, FIRST Baclofen, Ozobax, Fleqsuvy, Lyvispah

Dosage Form

oral tablet (5 mg, 10 mg, 20 mg), oral granule (5 mg, 10 mg, 20 mg), oral liquid (5 mg/5 mL), oral suspension (1 mg/mL, 5 mg/mL)

Drug Class

skeletal muscle relaxants

Pharmacokinetics

Absorption

Baclofen is well absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations typically reached within 2 hours. The oral bioavailability of baclofen is approximately 70-80%, with some first-pass metabolism reducing systemic availability. Food intake does not significantly affect the absorption rate but may delay peak plasma levels. Absorption occurs primarily in the small intestine, and baclofen’s water solubility facilitates its gastrointestinal uptake. Clinical studies indicate consistent absorption profiles that support predictable dosing regimens in spasticity management.

Distribution

Following absorption, baclofen is distributed throughout the body with a volume of distribution ranging between 0.7 to 1 L/kg, indicating moderate tissue penetration. Baclofen crosses the blood-brain barrier to exert central effects; however, its penetration is limited compared to other centrally acting muscle relaxants, which influences dosage requirements. It exhibits low plasma protein binding (approximately 30%), allowing significant free drug availability. Distribution is also noted into cerebrospinal fluid when administered intrathecally, providing localized spinal cord effects in resistant cases.

Metabolism

Baclofen undergoes minimal hepatic metabolism, with approximately 15% being metabolized predominantly via deamination and demethylation pathways. The majority of baclofen remains unchanged in systemic circulation, which reduces the risk of drug interactions mediated through hepatic enzyme induction or inhibition. The limited metabolism also implies relatively stable pharmacokinetics in patients with hepatic impairment but necessitates caution in renal dysfunction, where elimination is affected.

Elimination

The primary route of elimination of baclofen is renal excretion of the unchanged drug, accounting for around 85% of the administered dose. The elimination half-life ranges from 3 to 4 hours in healthy individuals but may be prolonged in renal impairment. Baclofen is efficiently cleared by the kidneys; thus, dosage adjustments are indicated in patients with reduced renal function to prevent accumulation and toxicity. Intrathecal baclofen is eliminated slower due to localized administration, necessitating specific dosing and monitoring protocols.

Dosage Forms

Adults

For adult patients with spasticity, baclofen is administered orally with a starting dose of 5 mg orally three times daily for 3 days. The dose is then typically titrated every 3 days in 5 mg increments to 10 mg, then 15 mg, and 20 mg three times daily. The maintenance dose is individualized according to therapeutic response and tolerability, with a maximum total daily dose of 80 mg (divided as 20 mg four times daily). Slow titration minimizes adverse effects and optimizes muscle spasm control.

Adolescents

In adolescents aged 12 years and older, baclofen dosing mirrors adult regimens. The initial dosing starts at 5 mg orally three times daily with upward titration every 3 days in 5 mg increments to achieve desired spasticity control. Maximum dosing should not exceed 80 mg per day divided into four doses. Pediatric dosing below 12 years has not been established and requires careful specialist assessment, often using intrathecal routes for severe cases.

Special Populations

In patients with renal impairment, dose adjustments are critical due to decreased clearance and prolonged elimination half-life, with lower initial doses and slower titration recommended. Hepatic impairment does not significantly affect baclofen pharmacokinetics but monitoring is advised due to patient variability. Elderly patients may be more sensitive to central nervous system effects and thus may require cautious dosing and monitoring. Special consideration is warranted during pregnancy and breastfeeding, as baclofen can induce withdrawal symptoms in neonates; use only if clearly needed and under medical supervision. The oral granule formulations are suitable for patients with swallowing difficulties and can be dissolved in liquids or soft foods, facilitating administration via feeding tubes if necessary.

Mechanism Of Action

Baclofen is a gamma-aminobutyric acid (GABA) derivative that acts as a selective agonist at GABA-B receptors, which are G-protein coupled receptors predominantly located in the central nervous system, especially in the spinal cord. Activation of GABA-B receptors by baclofen leads to hyperpolarization of neurons via increased potassium conductance and reduced calcium influx, resulting in decreased neurotransmitter release. This inhibitory effect primarily suppresses excitatory neurotransmission from primary afferent terminals involved in reflex muscle spasms, effectively reducing muscle spasticity.

At the cellular level, baclofen dampens monosynaptic and polysynaptic reflexes by inhibiting excitatory interneurons and motoneurons in the spinal cord. The suppression of excitatory neurotransmitter release such as glutamate and substance P contributes to relief of muscle hyperactivity and rigidity. Additionally, baclofen modulates the release of excitatory amino acids in the central nervous system, further promoting muscle relaxation.

Baclofen’s mechanism is distinct from other skeletal muscle relaxants such as dantrolene, which act peripherally on the muscle fiber by interfering with calcium release. In contrast, baclofen’s central action targets neural pathways underlying spasticity, making it effective in conditions involving upper motor neuron lesions like multiple sclerosis or spinal cord injury.

Clinical implications of this mechanism involve the ability of baclofen to reduce painful muscle spasms, improve mobility, and enhance patient function. Moreover, intrathecal administration allows targeted delivery to spinal receptors, maximizing central effects while minimizing systemic exposure and side effects. Research continues to explore baclofen’s effects on spinal neuronal circuits and its potential neuroprotective roles in neural injury models.

Pharmacological Actions

Agonist at central nervous system GABA-B receptors
Inhibition of excitatory neurotransmitter release in spinal cord neurons
Reduction of muscle spasticity by decreasing frequency and severity of muscle spasms
Suppression of monosynaptic and polysynaptic spinal reflexes
Muscle relaxant effect via neuronal hyperpolarization
Central nervous system depressant effects leading to decreased neuronal excitability
Antispastic agent used in neurological disorders
Modulation of neurotransmitter release attenuating abnormal muscle tone

Therapeutic Clinical Uses

Management of spasticity due to multiple sclerosis
Treatment of muscle stiffness and spasms following spinal cord injury or disease
Relief of spasticity and associated pain in cerebral palsy in patients older than 12 years
Adjunctive therapy in neurological disorders with muscle hypertonia
Off-label use in conditions with spasticity such as stroke sequelae
Reduction of flexor and extensor spasms to improve mobility and comfort
Use in intrathecal form for severe refractory spasticity
Symptomatic relief of muscle hyperactivity and associated impairments

Side Or Adverse Effects

Drowsiness and sedation, especially during initial therapy or dose escalation
Dizziness and weakness leading to impaired balance
Fatigue and general malaise
Confusion and hallucinations in rare cases, particularly in elderly or those with CNS disorders
Muscle weakness which may impair motor function if overdosed
Gastrointestinal disturbances such as nausea or constipation
Pruritus and tingling sensations in extremities reported occasionally
Withdrawal symptoms including tremors, seizures, and increased spasticity with abrupt cessation
Rare hypersensitivity reactions including rash, angioedema, or respiratory difficulty
Potential for respiratory depression at high doses or with CNS depressants

Precautions

Use with caution in patients with a history of seizure disorders due to potential CNS excitability changes
Monitor closely in patients with mental illness or psychosis for exacerbation of symptoms
Cautiously use in patients with impaired balance or motor coordination to avoid falls
Adjust dosing gradually to minimize side effects and withdrawal risks
Careful assessment in patients with renal impairment to prevent drug accumulation
Avoid concomitant use with CNS depressants to reduce risk of excessive sedation
Pregnant and breastfeeding women should use only if benefits outweigh risks; potential neonatal withdrawal
Gradual tapering required to avoid serious withdrawal syndrome
Risk of increased ovarian cyst development; monitor female patients accordingly
Avoid abrupt discontinuation especially in long-term users

Warnings

Avoid activities requiring mental alertness until effects of baclofen are known
Do not suddenly stop baclofen therapy to prevent withdrawal symptoms such as seizures and hallucinations
Alcohol consumption may exacerbate sedative side effects and increase fall risk
Use caution when combining with opioids, benzodiazepines, or other muscle relaxants
Warning for respiratory depression at high doses or in patients with respiratory compromise
Potential for serious allergic reactions requiring immediate medical attention
Risk of severe drowsiness or coma in overdose cases
Monitor mental state as baclofen may induce confusion or psychosis in susceptible individuals
Keep out of reach of children to prevent accidental ingestion and toxicity
Intrathecal formulations require specialist management due to dosing and complication risks

Contraindications

Known hypersensitivity or allergic reaction to baclofen or formulation components
Severe renal impairment without dose adjustment due to risk of accumulation
Patients with active psychosis or uncontrolled mental illness without supervision
Concomitant use with medications that produce profound CNS depression unless closely monitored
Use in patients with spasticity requiring active muscle tone for safe movement (e.g., early rehabilitation)
Use caution in patients with epilepsy due to potential seizure exacerbation
Intrathecal baclofen contraindicated in infections near catheter site
Contraindicated in patients unable to adhere to dosing regimen or monitoring protocols
Avoid use in patients with known hypersensitivity to oral suspension excipients
Use caution in patients with hypotension or cardiovascular instability

Drug Interactions

Additive CNS depressant effects with opioids, benzodiazepines, barbiturates, and alcohol leading to increased sedation and respiratory depression
Potential interaction with antihypertensive drugs may cause enhanced blood pressure lowering and dizziness
Concomitant use with muscle relaxants may increase risk of muscle weakness and sedation
Drugs altering renal function can affect baclofen clearance and increase toxicity risk
No significant hepatic metabolism; thus, minimal interaction with cytochrome P450 enzymes expected
Avoid use with seizure threshold-lowering agents unless medically justified
Concurrent use with anesthetics may potentiate CNS depressant effects
Interactions with herbal CNS depressants (e.g., valerian, kava) can enhance sedation
Potential interaction with drugs causing electrolyte imbalances that may modify neuromuscular excitability
Drug interaction profile necessitates close monitoring when initiating or discontinuing concomitant therapies

Preparations Of The Drug

Oral tablets: 5 mg, 10 mg, and 20 mg strengths for systemic administration
Oral granules: 5 mg, 10 mg, and 20 mg packets for direct oral administration or mixing with liquids or soft foods
Oral liquid: 5 mg per 5 mL formulation, suitable for precise dosing and patients with swallowing difficulties
Oral suspension: 1 mg/mL and 5 mg/mL concentrations for flexible dosing, including pediatric tailoring
Intrathecal baclofen injection for direct spinal administration in refractory spasticity cases
Various branded products include Lioresal, Fleqsuvy, Gablofen, Lyvispah, Ozobax with similar formulations
Multidose bottles, single-dose packets for granules, and premeasured dosing devices accompany preparations
Storage recommendations vary: some liquid forms require refrigeration (Ozobax), others stored at room temperature